Merck KGaA takes a punt on Inspirna’s novel approach
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
